| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Proliferative spasmolytic polypeptide-expressing metaplasia in gastric carcinogenesis: Stem cell origins, lineage plasticity, and clinical implications
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wei-Jian Zhang, Yan-Zi Huang, Qiang Chen, Shu-Tong Zheng, Hui-Shan Yuan, Xin-Bo Chen, Yi-Zhong Liang, Xin-Xin Hong, Yi-Fei Xu, Hai-Wen Li, Yong Gao and Shao-Ju Guo |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82608567, 82374348, and 82305133 |
| Guangdong Medical Research Foundation |
B2026159 |
| Shenzhen Science and Technology Program |
JCYJ20230807094659030 |
| Sanming Project of Medicine in Shenzhen |
SZZYSM202211002 |
| Shenzhen High-level Hospital Construction Fund |
|
|
| Corresponding Author |
Shao-Ju Guo, Department of Gastroenterology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, No. 1 Fuhua Road, Futian, Shenzhen 518033, Guangdong Province, China. gsj1080@163.com |
| Key Words |
Spasmolytic polypeptide-expressing metaplasia; Gastric carcinogenesis; Gastric stem cells; Intestinal metaplasia; Cellular plasticity; Chronic inflammation |
| Core Tip |
Spasmolytic polypeptide-expressing metaplasia (SPEM) encompasses distinct injury-associated states in the gastric corpus. This review focuses on the stem/progenitor-cell origins and lineage plasticity of proliferative SPEM, comparing evidence for contributions from corpus isthmus stem/progenitor cells, the mucous neck–chief transitional lineage, and chief-cell-labeled populations. We distinguish transient repair-associated SPEM from persistent proliferative states associated with chronic inflammation, oncogenic signaling, intestinal differentiation, and dysplasia. Although SPEM is not an obligatory intermediate of gastric carcinogenesis, persistent proliferative SPEM is closely associated with progression-related changes. Reproducible pathological criteria and longitudinal human validation are required before proliferative SPEM can be incorporated into clinical risk stratification. |
| Citation |
Zhang WJ, Huang YZ, Chen Q, Zheng ST, Yuan HS, Chen XB, Liang YZ, Hong XX, Xu YF, Li HW, Gao Y, Guo SJ. Proliferative spasmolytic polypeptide-expressing metaplasia in gastric carcinogenesis: Stem cell origins, lineage plasticity, and clinical implications. World J Stem Cells 2026; In press
|
| PDF |
126709-in-press.pdf
|
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
